|
1.Twerenbold, R., et al., Impact of high-sensitivity cardiac troponin on use of coronary angiography, cardiac stress testing, and time to discharge in suspected acute myocardial infarction. Eur Heart J, 2016. 2.Thygesen, K., et al., Third universal definition of myocardial infarction. J Am Coll Cardiol, 2012. 60(16): p. 1581-98. 3.Mehta, P.K., J. Wei, and N.K. Wenger, Ischemic heart disease in women: a focus on risk factors. Trends Cardiovasc Med, 2015. 25(2): p. 140-51. 4.Mozaffarian, D., et al., Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation, 2015. 131(4): p. e29-322. 5.Murray, C.J. and A.D. Lopez, Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet, 1997. 349(9064): p. 1498-504. 6.Cheng, Y., et al., Secular trends in coronary heart disease mortality, hospitalization rates, and major cardiovascular risk factors in Taiwan, 1971-2001. Int J Cardiol, 2005. 100(1): p. 47-52. 7.Boersma, E., et al., Acute myocardial infarction. Lancet, 2003. 361(9360): p. 847-58. 8.Van de Werf, F., et al., Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J, 2008. 29(23): p. 2909-45. 9.Cervellin, G. and G. Rastelli, The clinics of acute coronary syndrome. Ann Transl Med, 2016. 4(10): p. 191. 10.Davis, T.M., et al., Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study. Diabetologia, 2004. 47(3): p. 395-9. 11.Valensi, P., L. Lorgis, and Y. Cottin, Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature. Arch Cardiovasc Dis, 2011. 104(3): p. 178-88. 12.Burgess, D.C., et al., Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J, 2010. 31(1): p. 92-9. 13.Chaitman, B.R., et al., The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation, 2009. 120(25): p. 2529-40. 14.Sheifer, S.E., T.A. Manolio, and B.J. Gersh, Unrecognized myocardial infarction. Ann Intern Med, 2001. 135(9): p. 801-11. 15.Toma, M., et al., Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. Am Heart J, 2010. 160(4): p. 671-7. 16.Omland, T., et al., Troponins in heart failure. Clin Chim Acta, 2015. 443: p. 78-84. 17.Thygesen, K., et al., Universal definition of myocardial infarction. Circulation, 2007. 116(22): p. 2634-53. 18.Chua, S., et al., Time courses of subcellular signal transduction and cellular apoptosis in remote viable myocardium of rat left ventricles following acute myocardial infarction: role of pharmacomodulation. J Cardiovasc Pharmacol Ther, 2009. 14(2): p. 104-15. 19.Antman, E., et al., Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarctionThe Joint European Society of Cardiology/ American College of Cardiology Committee∗. Journal of the American College of Cardiology, 2000. 36(3): p. 959-969. 20.Kramer, C.M., et al., Multimodality imaging of myocardial injury and remodeling. J Nucl Med, 2010. 51 Suppl 1: p. 107s-121s. 21.Mueller, C., et al., Rapid rule out of acute myocardial infarction: novel biomarker-based strategies. Eur Heart J Acute Cardiovasc Care, 2016. 22.Vasan, R.S., Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation, 2006. 113(19): p. 2335-62. 23.Chan, D. and L.L. Ng, Biomarkers in acute myocardial infarction. BMC Med, 2010. 8: p. 34. 24.Lewandrowski, K.B., Cardiac markers of myocardial necrosis: a history and discussion of milestones and emerging new trends. Clin Lab Med, 2014. 34(1): p. 31-41, xi. 25.Gibler, W.B., et al., Myoglobin as an early indicator of acute myocardial infarction. Ann Emerg Med, 1987. 16(8): p. 851-6. 26.Jaffe, A.S., et al., It's time for a change to a troponin standard. Circulation, 2000. 102(11): p. 1216-20. 27.Schreier, T., L. Kedes, and R. Gahlmann, Cloning, structural analysis, and expression of the human slow twitch skeletal muscle/cardiac troponin C gene. J Biol Chem, 1990. 265(34): p. 21247-53. 28.Gaze, D.C. and P.O. Collinson, Multiple molecular forms of circulating cardiac troponin: analytical and clinical significance. Ann Clin Biochem, 2008. 45(Pt 4): p. 349-55. 29.Ricchiuti, V., et al., Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim. Clin Chem, 1998. 44(9): p. 1919-24. 30.Adams, J.E., 3rd, et al., Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation, 1993. 88(1): p. 101-6. 31.Larue, C., et al., Cardiac-specific immunoenzymometric assay of troponin I in the early phase of acute myocardial infarction. Clin Chem, 1993. 39(6): p. 972-9. 32.Cummins, B., M.L. Auckland, and P. Cummins, Cardiac-specific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J, 1987. 113(6): p. 1333-44. 33.Apple, F.S., et al., Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem, 2012. 58(1): p. 54-61. 34.Adams, J.E., 3rd, et al., Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin Chem, 1994. 40(7 Pt 1): p. 1291-5. 35.Mills, N.L., et al., Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. Jama, 2011. 305(12): p. 1210-6. 36.Christenson, E. and R.H. Christenson, Characteristics of cardiac troponin measurements. Coron Artery Dis, 2013. 24(8): p. 698-704. 37.Conrad, M.J. and P. Jarolim, Cardiac troponins and high-sensitivity cardiac troponin assays. Clin Lab Med, 2014. 34(1): p. 59-73, vi. 38.de Antonio, M., et al., Head-to-head comparison of high-sensitivity troponin T and sensitive-contemporary troponin I regarding heart failure risk stratification. Clin Chim Acta, 2013. 426: p. 18-24. 39.Cho, I.H., et al., Chemiluminometric enzyme-linked immunosorbent assays (ELISA)-on-a-chip biosensor based on cross-flow chromatography. Anal Chim Acta, 2009. 632(2): p. 247-55. 40.Hayes, M.A., et al., Demonstration of sandwich and competitive modulated supraparticle fluoroimmunoassay applied to cardiac protein biomarker myoglobin. Analyst, 2009. 134(3): p. 533-41. 41.Tuteja, S.K., et al., Graphene-gated biochip for the detection of cardiac marker Troponin I. Anal Chim Acta, 2014. 809: p. 148-54. 42.Liu, J., et al., Adenovirus-mediated delivery of bFGF small interfering RNA reduces STAT3 phosphorylation and induces the depolarization of mitochondria and apoptosis in glioma cells U251. J Exp Clin Cancer Res, 2011. 30: p. 80. 43.Wu, W.-Y., et al., PDMS gold nanoparticle composite film-based silver enhanced colorimetric detection of cardiac troponin I. Sensors and Actuators B: Chemical, 2010. 147(1): p. 298-303. 44.Fathil, M.F., et al., Diagnostics on acute myocardial infarction: Cardiac troponin biomarkers. Biosens Bioelectron, 2015. 70: p. 209-20. 45.Dittmer, W.U., et al., Rapid, high sensitivity, point-of-care test for cardiac troponin based on optomagnetic biosensor. Clin Chim Acta, 2010. 411(11-12): p. 868-73. 46.Gan, S.D. and K.R. Patel, Enzyme immunoassay and enzyme-linked immunosorbent assay. J Invest Dermatol, 2013. 133(9): p. e12. 47.Engvall, E. and P. Perlmann, Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry, 1971. 8(9): p. 871-4. 48.Dodeigne, C., L. Thunus, and R. Lejeune, Chemiluminescence as diagnostic tool. A review. Talanta, 2000. 51(3): p. 415-39. 49.Pei, X., et al., Sandwich-type immunosensors and immunoassays exploiting nanostructure labels: A review. Anal Chim Acta, 2013. 758: p. 1-18. 50.Boeckx, R.L., Chemiluminescence: applications for the clinical laboratory. Hum Pathol, 1984. 15(2): p. 104-11. 51.Wang, C., et al., Chemiluminescent Immunoassay and its Applications. Chinese Journal of Analytical Chemistry, 2012. 40(1): p. 3-10. 52.Qureshi, A., Y. Gurbuz, and J.H. Niazi, Biosensors for cardiac biomarkers detection: A review. Sensors and Actuators B: Chemical, 2012. 171-172: p. 62-76. 53.Hicks, J.M., Fluorescence immunoassay. Human Pathology, 1984. 15(2): p. 112-116. 54.Fan, X., et al., Sensitive optical biosensors for unlabeled targets: a review. Anal Chim Acta, 2008. 620(1-2): p. 8-26. 55.Peacock, W.F., et al., Can a Point-of-Care Troponin I Assay be as Good as a Central Laboratory Assay? A MIDAS Investigation. Ann Lab Med, 2016. 36(5): p. 405-12. 56.Sluss, P.M., Methodologies for measurement of cardiac markers. Clin Lab Med, 2014. 34(1): p. 167-85, viii. 57.Farah, C.S., et al., Structural and regulatory functions of the NH2- and COOH-terminal regions of skeletal muscle troponin I. J Biol Chem, 1994. 269(7): p. 5230-40. 58.Farah, C.S. and F.C. Reinach, The troponin complex and regulation of muscle contraction. Faseb j, 1995. 9(9): p. 755-67. 59.Liao, R., C.K. Wang, and H.C. Cheung, Coupling of calcium to the interaction of troponin I with troponin C from cardiac muscle. Biochemistry, 1994. 33(42): p. 12729-34. 60.Nakayama, S. and R.H. Kretsinger, Evolution of the EF-hand family of proteins. Annu Rev Biophys Biomol Struct, 1994. 23: p. 473-507. 61.Kobayashi, T., et al., Extensive interactions between troponins C and I. Zero-length cross-linking of troponin I and acetylated troponin C. Biochemistry, 1995. 34(34): p. 10946-52. 62.Morimoto, S. and I. Ohtsuki, Ca2+ binding to cardiac troponin C in the myofilament lattice and its relation to the myofibrillar ATPase activity. Eur J Biochem, 1994. 226(2): p. 597-602. 63.Sorenson, M.M., et al., Concerted action of the high affinity calcium binding sites in skeletal muscle troponin C. J Biol Chem, 1995. 270(17): p. 9770-7. 64.Gordon, A.M., E. Homsher, and M. Regnier, Regulation of contraction in striated muscle. Physiol Rev, 2000. 80(2): p. 853-924. 65.Pearlstone, J.R. and L.B. Smillie, Evidence for two-site binding of troponin I inhibitory peptides to the N and C domains of troponin C. Biochemistry, 1995. 34(21): p. 6932-40. 66.Eriksson, S., et al., Negative interference in cardiac troponin I immunoassays from a frequently occurring serum and plasma component. Clin Chem, 2003. 49(7): p. 1095-104. 67.Speth, M., K. Seibold, and N. Katz, Interaction between heparin and cardiac troponin T and troponin I from patients after coronary bypass surgery. Clinical Biochemistry, 2002. 35(5): p. 355-362. 68.Verrecchio, A., et al., Design of peptides with high affinities for heparin and endothelial cell proteoglycans. J Biol Chem, 2000. 275(11): p. 7701-7. 69.Chan, C.P., et al., Evidence-based point-of-care diagnostics: current status and emerging technologies. Annu Rev Anal Chem (Palo Alto Calif), 2013. 6: p. 191-211. 70.Anderson, J.L., et al., 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2011. 123(18): p. e426-579. 71.Hamm, C.W., et al., ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2011. 32(23): p. 2999-3054. 72.Thygesen, K., et al., How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J, 2012. 33(18): p. 2252-7. 73.Panteghini, M., Assay-related issues in the measurement of cardiac troponins. Clin Chim Acta, 2009. 402(1-2): p. 88-93. 74.Jarolim, P., Overview of cardiac markers in heart disease. Clin Lab Med, 2014. 34(1): p. 1-14, xi. 75.Glatz, J.F., et al., Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. Biochim Biophys Acta, 1988. 961(1): p. 148-52. 76.Kleine, A.H., et al., Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem, 1992. 116(1-2): p. 155-62. 77.McCann, C.J., et al., Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J, 2008. 29(23): p. 2843-50. 78.Ruff, C.T., et al., Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study. J Thromb Thrombolysis, 2013. 36(4): p. 361-7.
|